Research Report Screener Results

Chart, Financials, Historical Prices, Industry, Insider, Messages, Profile, Reports, Research, SEC Filings, more...

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 21)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A ACTI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for ACTI: the economy's impact on ACTI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
6-Feb-10 Reuters Investment Profile N/A Active Biotech AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ACTI , CML , PKT , TIGR , VDSI , VMW -- COMPUTERS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ACTIVIDENTITY -- ACTI 1 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ACTIVIDENTITY CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public CHEMICALS Companies - Graham & Whiteside listing 8 $80 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public BIOTECHNOLOGY Companies - Graham & Whiteside listing 6 $80 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public SERVICES Companies - Graham & Whiteside listing 31 $165 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public PHARMACEUTICALS Companies - Graham & Whiteside listing 8 $80 View Abstract
Next 11

Independent Reports (Showing 1 to 10 of 21)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A ACTI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
9-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for ACTI: the economy's impact on ACTI's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
6-Feb-10 Reuters Investment Profile N/A Active Biotech AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ACTI , CML , PKT , TIGR , VDSI , VMW -- COMPUTERS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ACTIVIDENTITY -- ACTI 1 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ACTIVIDENTITY CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public CHEMICALS Companies - Graham & Whiteside listing 8 $80 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public BIOTECHNOLOGY Companies - Graham & Whiteside listing 6 $80 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public SERVICES Companies - Graham & Whiteside listing 31 $165 View Abstract
1-Feb-10 Graham & Whiteside Limited Graham & Whiteside SWEDEN - Public PHARMACEUTICALS Companies - Graham & Whiteside listing 8 $80 View Abstract
Next 11

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.